MANAGING RISK AND AUTOMATION IN THE CLOSE PROCESS
Boston Scientific is a $10 billion global provider of medical solutions with 38,000 employees around the world. Boston Scientific products are used to help diagnose or treat complex diseases and conditions across multiple fields: cardiovascular, respiratory, digestive, neurological, urological and pelvic health.
It’s a complex business and in this video, sponsored by Trintech, a leader on close automation, Rodéric Lemaire, EMEA process lead for the Record-To-Report (R2R) process talks to Gary Simon, FSN Chief Executive about the challenges of being a global process owner and how to manage risk and automation in the close process. In particular they touch upon, creating a culture of change, ensuring adequate levels of risk management and how to best fill the gaps in process standardisation and automation.
Video Series: How to drive automation of the financial close
This video entitled “Managing risk and automation in the close process” forms part of a wider video series to be aired over the next 3 months. FSN’s Gary Simon will be carrying out a series of interviews with inspiring finance leaders, kindly commissioned by Trintech, exploring how finance can drive automation, especially around the close.
Other videos in the series include: Are you missing out on financial close automation?
Related LinkedIn discussion
One of 2021’s most lively discussions looks at “why half of finance automation projects are failing and how can we turn the tide? The FSN Modern Finance Community discussed this issue at great length. Read the 86 comments here.
WHY ARE HALF OF FINANCE AUTOMATION PROJECTS FAILING? FSN’s newly released research shows that 46% of finance automation initiatives failed to improve process efficiency and throughput!
HOW CAN CFOs MAKE A BETTER BUSINESS CASE FOR INVESTMENT IN AUTOMATION?” What do you do if the board cannot see the light? How do you persuade a reluctant board to invest? How can you make the best possible business case for finance automation?